溶液中ATAD2溴结构域聚集行为的研究
收稿日期: 2022-04-06
网络出版日期: 2022-06-01
基金资助
国家重点基础研究发展计划（“973”计划）资助项目(2017YFA0505400);国家重点基础研究发展计划（“973”计划）资助项目(2018YFE0202300);国家重点基础研究发展计划（“973”计划）资助项目(2018YFA0704002)
The Aggregation of ATAD2 Bromodomain in Solution
Received date: 2022-04-06
Online published: 2022-06-01
三磷酸腺苷酶家族蛋白2（ATAD2）是一种染色质调节因子. 它的异常表达与多种恶性肿瘤的发生和发展密切相关，因此还被称为致癌转录辅助因子. ATAD2由ATP酶结构域和溴结构域组成. 其中，溴结构域可以特异性识别并结合组蛋白末端的乙酰化赖氨酸位点，调控染色体重构和转录，但其功能相关的很多结构特征并未可知. 我们首先发现ATAD2溴结构域在溶液中易发生聚集. 然后以核磁共振（NMR）和圆二色谱（CD）为主要研究手段，从环境因素和结构因素两方面对ATAD2溴结构域的聚集机理进行了初步探讨，发现该聚集行为伴有结构变化，并可能与功能相关. 本研究可能为ATAD2溴结构域抑制剂的研发提供新的思路.
王远方 , 王小花 , 舒畅 , 张许 , 刘买利 , 曾丹云 . 溶液中ATAD2溴结构域聚集行为的研究[J]. 波谱学杂志, 2023 , 40(2) : 169 -178 . DOI: 10.11938/cjmr20222993
ATPase family AAA domain-containing protein 2 (ATAD2) is a chromatin regulator, also known as an oncogenic transcription cofactor. Its abnormal expression is closely related to the occurrence and development of various malignant tumors. ATAD2 consists of two domains: the ATPase domain and the bromodomain. The bromodomain can specifically recognize and interact with the acetylated lysines in proteins, which regulates the refactoring and transcription of chromosomes. In this work, we found that ATAD2 bromodomains are aggregated under normal solution conditions. Considering the possible impact of aggregation on the interaction between ATAD2 bromodomain and acetylated histone tail, we preliminarily investigated the aggregation of ATAD2 bromodomains mainly by nuclear magnetic resonance (NMR) and circular dichroism (CD) spectra. The results suggested that the aggregation is accompanied with structure alteration and possibly related to the physiological functions of cells. This study may provide new clues for the development of ATAD2 bromodomain inhibitors.
Key words： nuclear magnetic resonance (NMR); ATAD2; bromodomain; aggregation
| [1] | EVANS C M, PHILLIPS M, MALONE K L, et al. Coordination of di-acetylated histone ligands by the ATAD2 bromodomain[J]. Int J Mol Sci, 2021, 22(17): 9128. |
| [2] | BOUSSOUAR F, JAMSHIDIKIA M, MOROZUMI Y, et al. Malignant genome reprogramming by ATAD2[J]. Biochim Biophys Acta-Gene Regul Mech, 2013, 1829(10): 1010-1014. |
| [3] | ZOU J X, REVENKO A S, LI L B, et al. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ER alpha, is required for coregulator occupancy and chromatin modification[J]. P Natl Acad Sci USA, 2007, 104(46): 18067-18072. |
| [4] | CIRO M, PROSPERINI E, QUARTO M, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors[J]. Cancer Res, 2009, 69(21): 8491-8498. |
| [5] | KRAKSTAD C, TANGEN I L, HOIVIK E A, et al. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma[J]. Oncotarget, 2015, 6(29): 28440-28452. |
| [6] | ZOU J X, GUO L L, REVENKO A S, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer[J]. Cancer Res, 2009, 69(8): 3339-3346. |
| [7] | FOURET R, LAFFAIRE J, HOFMAN P, et al. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma[J]. Clinical Cancer Research, 2012, 18(20): 5606-5616. |
| [8] | MURAKAMI H, ITO S, TANAKA H, et al. Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis[J]. Anticancer Res, 2013, 33(10): 4299-4307. |
| [9] | CARON C, LESTRAT C, MARSAL S, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers[J]. Oncogene, 2010, 29(37): 5171-5181. |
| [10] | SHANG P, MENG F L, LIU Y D, et al. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis[J]. Tumor Biology, 2015, 36(6): 4479-4485. |
| [11] | HONG S, BI M, YAN Z, et al. Silencing of ATPase family AAA domain-containing protein 2 inhibits migration and invasion of colorectal cancer cells[J]. Neoplasma, 2016, 63(6): 846-855. |
| [12] | CHEN D, MARUSCHKE M, HAKENBERG O, et al. TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma[J]. Urology, 2017, 102: 265. e1-265.e7. |
| [13] | SNIDER J, THIBAULT G, HOURY W A. The AAA plus superfamily of functionally diverse proteins[J]. Genome Biol, 2008, 9(4): 216. |
| [14] | HANSON P I, WHITEHEART S W. AAA+ proteins: Have engine, will work[J]. Nat Rev Mol Cell Biol, 2005, 6(7): 519-529. |
| [15] | ZENG L, ZHOU M M. Bromodomain: an acetyl-lysine binding domain[J]. FEBS Lett, 2002, 513(1): 124-128. |
| [16] | FILIPPAKOPOULOS P, PICAUD S, MANGOS M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family[J]. Cell, 2012, 149(1): 214-231. |
| [17] | PONCET-MONTANGE G, ZHAN Y A, BARDENHAGEN J P, et al. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2[J]. Biochem J, 2015, 466(3): 37-46. |
| [18] | MOROZUMI Y, BOUSSOUAR F, TAN M J, et al. Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells[J]. J Mol Cell Biol, 2016, 8(4): 349-362. |
| [19] | FILIPPAKOPOULOS P, PICAUD S, MANGOS M, et al. Histone Recognition and large-scale structural analysis of the human bromodomain family[J]. Cell, 2012, 149(1): 214-231. |
| [20] | OLZSCHA H, FEDOROV O, KESSLER B M, et al. CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation[J]. Cell Chem Biol, 2017, 24(1): 9-23. |
| [21] | HARNER M J, CHAUDER B A, PHAN J, et al. Fragment-based screening of the bromodomain of ATAD2[J]. J Med Chem, 2014, 57(22): 9687-9692. |
| [22] | GAY J C, ECKENROTH B E, EVANS C M, et al. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain[J]. Proteins, 2019, 87(2): 157-167. |
/
| 〈 |
|
〉 |